Sage's depression drug succeeds in mid-stage study, shares soar

(Reuters) - Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal of reducing symptoms in a mid-stage study, sending its shares soaring 52.3 percent in premarket trading.